#1 Clinical Trials Search in Europe

Skin Autograft

This article explores the use of skin autografts in clinical trials for patients undergoing reconstructive surgery after basal cell carcinoma removal. Skin autografts are a type of living tissue equivalent that uses a patient’s own skin cells to create a personalized treatment. The trials aim to evaluate the safety, feasibility, and effectiveness of this innovative approach compared to traditional methods.

Table of Contents

What is SKIN AUTOGRAFT?

SKIN AUTOGRAFT is an innovative medical treatment being studied for use in reconstructive surgery for patients with basal cell carcinoma. It is classified as a living tissue equivalent, which means it’s designed to mimic the properties of natural human skin[1]. This treatment is currently being investigated in a Phase II clinical trial to evaluate its safety and effectiveness compared to traditional skin grafting techniques.

Medical Conditions Treated

The primary medical condition being targeted by SKIN AUTOGRAFT is reconstructive skin surgery in basal cell cancer, specifically following Mohs surgery[1]. Mohs surgery is a precise surgical technique used to treat skin cancer by progressively removing thin layers of cancer-containing skin and examining them until only cancer-free tissue remains.

How It Works

SKIN AUTOGRAFT is a type of nanostructured autologous artificial skin based on a fibrin matrix combined with either agarose or hyaluronic acid. Here’s a breakdown of what this means:

  • Autologous: The treatment uses the patient’s own cells, reducing the risk of rejection.
  • Nanostructured: The skin substitute is engineered at a very small scale, allowing for precise control of its properties.
  • Fibrin matrix: Fibrin is a protein involved in blood clotting and wound healing, providing a scaffold for cell growth.
  • Agarose or hyaluronic acid: These substances help create a structure that mimics natural skin tissue.

The artificial skin is designed to be surgically implanted into the area where skin cancer has been removed, potentially offering a more advanced alternative to traditional skin grafts[1].

Clinical Trial Objectives

The main objectives of the clinical trial for SKIN AUTOGRAFT are:

  1. Safety: To confirm that the use of this artificial skin is safe, based on the incidence of adverse events during implantation and follow-up.
  2. Feasibility: To verify that the surgical implant is practical in terms of its ability to be sutured, attach to the recipient tissue, maintain integrity, and facilitate wound healing.
  3. Efficacy: To analyze whether SKIN AUTOGRAFT is as effective or more effective than traditional autografts in terms of wound healing and overall outcomes.

Secondary objectives include comparing the histological properties of the implanted artificial skin to natural skin, studying skin homeostasis, analyzing ultrasound differences, comparing pain levels, assessing scar quality and impact on quality of life, and conducting an economic evaluation of the treatment[1].

Eligibility Criteria

To participate in the clinical trial for SKIN AUTOGRAFT, patients must meet certain criteria. Some key inclusion criteria are:

  • Adults aged 18 or older
  • Diagnosed with basal cell carcinoma on the scalp, torso, or extremities
  • Lesions that require Mohs surgery and cannot be closed with direct suture or flaps

Some exclusion criteria include:

  • Locally advanced basal cell carcinoma with deep tissue infiltration
  • Lesions on the face (except for frontal-lateral area and temple)
  • Pregnant or breastfeeding women
  • Known allergies to certain antibiotics used in the manufacturing process

It’s important to note that these are just some of the criteria, and a healthcare professional would need to assess each individual case[1].

Safety and Efficacy

The clinical trial is designed to carefully evaluate the safety and efficacy of SKIN AUTOGRAFT. Safety measures include monitoring for adverse events, complications, and sequelae in the healing process. Efficacy will be assessed through various means, including:

  • Percentage of epithelialization (skin healing) 3 weeks after surgery
  • Time until stitches can be removed
  • Time until complete healing
  • Pain levels experienced by patients
  • Aesthetic appearance of the treated area
  • Impact on quality of life

Additionally, advanced techniques such as doppler ultrasound, cutaneous homeostasis studies, and histological tests will be used to evaluate the structural and functional properties of the treated skin[1].

Potential Benefits

While the full benefits of SKIN AUTOGRAFT are still being studied, potential advantages over traditional skin grafts may include:

  • Improved healing and integration with surrounding tissue
  • Reduced pain and complications at the donor site (as no separate donor site may be needed)
  • Better aesthetic outcomes
  • Improved quality of life for patients

It’s important to remember that these potential benefits are still being investigated in the clinical trial, and more research is needed to confirm the advantages of this innovative treatment[1].

Aspect Details
Study Type Phase II clinical trial
Treatment Nanostructured autologous artificial skin based on fibrin matrix with agarose or hyaluronic acid
Condition Basal cell carcinoma requiring reconstructive surgery
Primary Objectives Safety and feasibility of skin autograft
Secondary Objectives Efficacy, histological comparison, skin homeostasis, ultrasound analysis, pain assessment, aesthetic quality, quality of life impact, economic evaluation
Key Inclusion Criteria Adults with basal cell carcinoma on scalp, torso, or extremities; requiring Mohs surgery
Key Exclusion Criteria Locally advanced basal cell carcinoma, facial lesions (except frontal-lateral and temple areas), urgent surgical needs, infected or poorly vascularized injuries
Primary Endpoints Adverse events, surgical suturability, graft adherence, and wound re-epithelialization
Secondary Endpoints Epithelialization percentage, pain levels, aesthetic appearance, quality of life, structural and functional skin properties, economic efficiency

FAQ

  • What is a skin autograft? A skin autograft is a living tissue equivalent made from a patient's own skin cells. It is used to cover and heal wounds, particularly after surgery for conditions like basal cell carcinoma.
  • Who is eligible for the skin autograft clinical trial? Eligible participants are adults (18 years or older) with basal cell carcinoma on the scalp, torso, or extremities, requiring Mohs surgery. The lesions must be of a size that doesn't allow for direct suture or flap closure.
  • What are the main objectives of the clinical trial? The main objectives are to confirm the safety of the skin autograft, verify its feasibility in terms of surgical implantation, and compare its effectiveness to traditional autografts in reconstructive surgery for basal cell carcinoma.
  • How is the effectiveness of the skin autograft measured? Effectiveness is measured by the percentage of epithelialization 21 days after surgery, time until complete healing, pain levels, aesthetic appearance, and quality of life indices. Additional tests include ultrasound, skin homeostasis studies, and histological examinations.
  • Are there any risks or side effects associated with skin autografts? The trial monitors for adverse events and reactions, including complications in wound healing. Potential early complications may include hematoma, infection, blistering, and graft loss. Late complications could involve necrosis, inflammation, abnormal healing, and pigmentation disorders.

Ongoing Clinical Trials on Skin Autograft

  • Study on Autologous Skin-Derived Keratinocytes and Fibroblasts for Patients with Basal Cell Carcinoma Undergoing Reconstructive Surgery

    Recruiting

    1 1
    Investigated drugs:
    Spain

Glossary

  • Basal Cell Carcinoma: A type of skin cancer that begins in the basal cells, which are responsible for producing new skin cells as old ones die off.
  • Mohs Surgery: A precise surgical technique used to treat skin cancer by progressively removing thin layers of cancer-containing skin until only cancer-free tissue remains.
  • Epithelialization: The process by which epithelial cells (cells that line the surfaces of your body) grow over and cover a wound.
  • Autograft: A tissue graft taken from one part of a person's body and transplanted to a different site on the same person.
  • Nanostructured: Having a structure manipulated on an extremely small scale, typically between 1 to 100 nanometers.
  • Fibrin Matrix: A network of fibrin proteins that forms a scaffold for tissue repair and regeneration.
  • Transepidermal Water Loss: The amount of water that passively evaporates through the skin to the external environment.
  • POSAS Scale: Patient and Observer Scar Assessment Scale, used to evaluate the appearance and characteristics of scars.
  • DLQI: Dermatology Life Quality Index, a questionnaire used to measure the impact of skin conditions on a patient's quality of life.
  • SCI: Skin Cancer Index, a tool used to assess the quality of life in patients with non-melanoma skin cancers.

References

  1. http://clinicaltrials.eu/trial/study-on-autologous-skin-derived-keratinocytes-and-fibroblasts-for-patients-with-basal-cell-carcinoma-undergoing-reconstructive-surgery/